Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ramón González-Manzano"'
Autor:
Juan J. Mata-Molanes, Joseba Rebollo-Liceaga, Elena Mª Martínez-Navarro, Ramón González Manzano, Antonio Brugarolas, Manel Juan, Manuel Sureda
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Therapeutic monoclonal antibodies (mAbs), including immune checkpoint inhibitors (ICIs), are an important breakthrough for the treatment of cancer and have dramatically changed clinical outcomes in a wide variety of tumours. However, clinical respons
Externí odkaz:
https://doaj.org/article/c4184db2acb74038845fae3fb3915c94
Autor:
Joseba Rebollo, Ramón González-Manzano, Manuel Sureda, Elena Ma Martínez, Elena Monedero, Pedro Bretcha, Antonio Brugarolas
Publikováno v:
Journal of Clinical Oncology. 40:e13000-e13000
e13000 Background: A small number of breast cancer patients develops long-lasting loco-regional cutaneous recurrent disease with a delayed appearance of systemic disease. We recently have observed a favourable immunological signature in one patient a
Autor:
Manuel Sureda, Ramón González-Manzano, Elena Monedero, Elena Ma Martínez, Jose Luis Ortega, Roman Rostagno, Joseba Rebollo, Juan José Mata, Antonio Brugarolas
Publikováno v:
Journal of Clinical Oncology. 38:e13509-e13509
e13509 Background: Personalized multidrug therapies improve outcomes in patients with drug resistant cancer. For 8 years we have been using microarray-based gene expression profiling (360 procedures) to improve drug selection (Rebollo J et al, 2017;
Autor:
Francisco José Fernández Fernández, Manuel Sureda, Elena Evgenyeva, Elena Maria Martinez-Navarro, Jerónimo Forteza, Antonio Brugarolas, Joseba Rebollo, Ramón González-Manzano, Belén Valenzuela
Publikováno v:
Clinical and Translational Oncology. 13:812-818
INTRODUCTION Epidermal growth factor receptor (EGFR) mutation related to tyrosine kinase inhibitors' (TKIs) responsiveness in non-small cell lung cancer (NSCLC) has become an important issue for therapeutic decision-making in NSCLC patients. MATERIAL
Autor:
Pedro Bretcha, Manuel Sureda, Francisco J. Fernández-Morejón, Ramón González-Manzano, Francisco Fernández-Latorre, Elena Ma Martínez, Joseba Rebollo, Jesús Vegas, José Farré, Antonio Brugarolas
Publikováno v:
Journal of Clinical Oncology. 32:e22173-e22173
e22173 Background: MP is potentially useful for the sensitivity and resistance prediction to conventional and targeted drugs, although the wide number of platforms and algorithms used makes validat...
Autor:
Manuel Sureda, Antonio Brugarolas, José Farré, Joseba Rebollo, Francisco J. Fernández-Morejón, Severino Rey, Ramón González-Manzano
Publikováno v:
Journal of Clinical Oncology. 31:e22120-e22120
e22120 Background: Genomic-based profiling of tumors is a promising approach that allows the selection of the optimal chemotherapy regimen minimizing the possibility of futile therapies. Preliminary clinical results by our group showing a 23% respons
Autor:
Juan Jose Perez-Ruixo, Ramón González-Manzano, Joseba Rebollo, Elena Navarro, Mario González-Sales, Belén Valenzuela, Carlos Perez-Ruixo, Vanessa Escudero
Publikováno v:
Cancer Research. 73:2213-2213
Background and objective: SN-38 is the active metabolite of irinotecan (CPT-11) and mainly responsible of hematological and intestinal toxicity after CPT-11 treatments. SN-38 is inactivated into SN-38G by uridine diphosphate glucuronosyltransferase (
Publikováno v:
Cancer Research. 70:4677-4677
Irinotecan and Anthracyclines (Topoisomerase I and II inhibitors, respectively) are widely used as antitumoral agents in cancer treatment. However, no data have been reported when used in combination. In this study we report the activity of biweekly